SCHEMBL22160852

SCHEMBL22160852

CC(C)(C)OC(=O)Nc1ccc2c(c1)CCN2

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
DRD2 P14416 2/20 0.43
DRD4 P21917 1/20 0.43
NR1I3 Q14994 5/20 0.43
CYP17A1 P05093 2/20 0.42
EPHX2 P34913 1/20 0.42
PLAU P00749 1/20 0.41
NAMPT P43490 1/20 0.41
LIPE Q05469 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PDE7A Q13946 1/20 0.40
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257597 0.92 PLAU (0.50) CA12CA1CA9DRD2NR1I3
SCHEMBL2229710 0.89 MEN1 (0.49) CA12CA1CA9DRD2NR1I3
SCHEMBL31351705 0.83 PARP11 (0.49) CA12CA1CA9NR1I3BRD4
SCHEMBL19996133 0.80 NPC1 (0.53) CA12CA1CA9DRD2NR1I3
SCHEMBL30476642 0.80 NPC1 (0.53) CA12CA1CA9DRD2NR1I3
SCHEMBL880654 0.80 NPC1 (0.51) DRD2DRD4PLAUMEN1KMT2A
SCHEMBL31488089 0.80 NPC1 (0.51) DRD2DRD4PLAUMEN1KMT2A
Hydrochloric Acid SCHEMBL853073 0.79 NPC1 (0.50) DRD2DRD4PLAUPDE7A
SCHEMBL5803358 0.78 HPGD (0.49) CA1DRD2DRD4PLAUMEN1
Pivalate SCHEMBL27666987 0.78 NPC1 (0.45) DRD2DRD4PLAUPDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 CN disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 US disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
CN-111315735-A Dihydrobenzimidazolones C4医药公司 2020-06-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 CA12 2756/4885CA1 2073/4885CA9 3882/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 CA12 2756/4885CA1 2073/4885CA9 3882/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 CA12 2756/4885CA1 2073/4885CA9 3882/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 CA12 2756/4885CA1 2073/4885CA9 3882/4885
US-11254672-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 CA12 2756/4885CA1 2073/4885CA9 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.